Trial Profile

An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tesidolumab (Primary)
Indications Paroxysmal nocturnal haemoglobinuria
Focus Proof of concept; Therapeutic Use
Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals

Most Recent Events

01 Nov 2024 The protocol has been amended to change in study time frame for primary endpoint LDH) Levels and addition in one more primary endpoint.
15 Jun 2023 Results assessing efficacy and safety of TESI and the effect of switching to IPTA monotherapy in PNH presented at the 28th Congress of the European Haematology Association
19 Jul 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com